Granted Patent
B2
US 12,527,874 · App. 17/554,792 · Granted Jan 20, 2026
Bioorthogonal compositions
Assignee:
Tambo, Inc.
A61K47/61A61K47/18A61K47/555A61K47/6903A61K47/6939A61K49/0032A61K49/0054A61K49/0073A61K51/0495A61K51/1213A61K51/1244A61P35/00C08B37/0084A61K9/0019A61K9/0024A61K31/337A61K31/35A61K31/453A61K38/08A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.
Claims (17)
1 . A therapeutic support composition comprising a tetrazine-containing group of formula
wherein
R 20 is alkyl;
wherein the tetrazine-containing group is covalently attached directly to a support through an amide and the support is a hyaluronic acid.
2 . The therapeutic support composition of claim 1 , wherein the support is a hydrogel.
3 . The therapeutic support composition of claim 1 , wherein the support is a particle.
4 . The therapeutic support composition of claim 3 , wherein the particle is a nanoparticle.
5 . The therapeutic support composition of claim 1 , comprising:
an azide-containing group of formula:
wherein L 10 is a linker; or
an alkyne-containing group of formula:
wherein L 11 is a linker.
6 . The therapeutic support composition of claim 5 , wherein each linker is a C 1 -C 10 -alkylene group.
7 . A therapeutic support composition comprising a particle, to which a tetrazine-containing group is attached, represented by the following formula
wherein:
R 20 is alkyl;
the particle is hyaluronic acid, and the tetrazine-containing group is covalently attached directly to the particle through an amide.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 16, 2022
From: MEJIA ONETO, JOSE
To: TAMBO, INC.
Reel/Frame 059287/0092 →
Continuity (10)
Continuation
15759056
Provisional Application
62381442
· Aug 30, 2016
Provisional Application
62357647
· Jul 1, 2016
Provisional Application
62344341
· Jun 1, 2016
Provisional Application
62327924
· Apr 26, 2016
Provisional Application
62387480
· Dec 24, 2015
Provisional Application
62242896
· Oct 16, 2015
Provisional Application
62216858
· Sep 10, 2015
References Cited (152)
US 5770229A
· Tanihara et al.
· 1998
[cited by applicant]
US 8552183B2
· Wiessler et al.
· 2013
[cited by applicant]
US 9421274B2
· Robillard et al.
· 2016
[cited by applicant]
US 9427482B2
· Rossin et al.
· 2016
[cited by applicant]
US 9463256B2
· Lub et al.
· 2016
[cited by applicant]
US 20060153893A1
· Matsuno et al.
· 2006
[cited by applicant]
US 20090304587A1
· Rubinstein et al.
· 2009
[cited by applicant]
US 20110223257A1
· Zhao et al.
· 2011
[cited by applicant]
US 20120034161A1
· Robillard et al.
· 2012
[cited by applicant]
US 20130302246A1
· Hilderbrand et al.
· 2013
[cited by applicant]
US 20140303123A1
· Baker, Jr. et al.
· 2014
[cited by applicant]
US 20160114046A1
· Brudno et al.
· 2016
[cited by applicant]
EP 1867638A1
· 2007
[cited by applicant]
EP 2716662A1
· 2014
[cited by applicant]
EP 2719400A2
· 2014
[cited by applicant]
JP 2009513696A
· 2009
[cited by applicant]
JP 2010036032A
· 2010
[cited by applicant]
WO WO2003000708A1
· 2003
[cited by applicant]
WO WO2003084571A1
· 2003
[cited by applicant]
WO 2009064738A2
· 2009
[cited by applicant]
WO WO2010051530A2
· 2010
[cited by applicant]
WO WO2011127149A1
· 2011
[cited by applicant]
WO WO2012012612A2
· 2012
[cited by applicant]
WO WO2012049624A1
· 2012
[cited by applicant]
WO WO2012074840A2
· 2012
[cited by applicant]
WO WO2012085789A1
· 2012
[cited by applicant]
WO WO2012153254A1
· 2012
[cited by applicant]
WO WO2012156918A1
· 2012
[cited by applicant]
WO WO2012156919A1
· 2012
[cited by applicant]
WO WO2012156920A1
· 2012
[cited by applicant]
WO WO2012165462A1
· 2012
[cited by applicant]
WO WO2012168512A2
· 2012
[cited by applicant]
WO WO2013187954A1
· 2013
[cited by applicant]
WO WO2014065860A1
· 2014
[cited by applicant]
WO WO2014081299A1
· 2014
[cited by applicant]
WO WO2014081300A1
· 2014
[cited by applicant]
WO WO2014081301A1
· 2014
[cited by applicant]
WO WO2014081303A1
· 2014
[cited by applicant]
WO WO2014117001A1
· 2014
[cited by applicant]
WO WO2014138186A1
· 2014
[cited by applicant]
WO WO2014200767A1
· 2014
[cited by applicant]
WO WO2014205126A1
· 2014
[cited by applicant]
WO WO2014134689A1
· 2015
[cited by applicant]
WO WO2015117235A1
· 2015
[cited by applicant]
WO WO2015139025A1
· 2015
[cited by applicant]
WO WO2015154082A1
· 2015
[cited by applicant]
WO 2016014799A1
· 2016
[cited by applicant]
WO 2017004192A1
· 2016
[cited by applicant]
Al-Dubai et al., “Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system,” Nanotechnology, Science and AQQlications, vol. 2011, No. 4, pp. 87-94 (2011).
[cited by applicant]
Alge et al., “Synthetically tractable click hydrogels for three-dimensional cell culture formed using tetrazine-norbornene chemistry,” Biomacromolecules, 2013, 14(4):949-953.
[cited by applicant]
Altin et al., “Fabrication of “Clickable” Hydrogels via Dendron-Polymer Conjugates,” Macromolecules, 2010, vol. 43, No. 8, pp. 3801-3808.
[cited by applicant]
Antoci et al., “The inhibition of
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, vol. 66, pp. 1-19.
[cited by applicant]
Blackman et al., “Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels-Alder Reactivity,” J. Am. Chem. Soc., 2008, vol. 130, pp. 13518-13519.
[cited by applicant]
Brudno et al., “In Vivo Targeting through Click Chemistry,” Chem. Med. Chem., 2015, vol. 10, pp. 617-620.
[cited by applicant]
Brudno et al., “On-demand drug delivery from local depots,” J. Control. Release, 2015, http://dx.doi.org/10.1016/j.jconrel.2015.09.011, 10 pages.
[cited by applicant]
Brudno et al., “Refilling drug delivery depots through the blood,” PNAS, 2014, 111(35):12722-12727.
[cited by applicant]
Brudno et al., “Replenishable drug depot to combat post-resection cancer recurrence,” Biomaterials, 2018, 178:373-382.
[cited by applicant]
Burdick et al., “Acellular Biomaterials: An Evolving Alternative to Cell-Based Therapies,” Science Translation Medicine, Mar. 13, 2013, vol. 5, Issue 176, 4 pages.
[cited by applicant]
Carlson et al., “Unraveling Tetrazine-Triggered Bioorthogonal Elimination Enables Chemical Tools for Ultrafast Release and Universal Cleavage,” J. Am. Chem. Soc., 2018, 140(10):3603-3612.
[cited by applicant]
Chung et al., “Ubiquitous Detection of Gram-Positive Bacteria with Bioorthogonal Magnetofluorescent Nanoparticles,” ACS NANO, 2011, vol. 5, No. 11, pp. 8834-8841, Supporting Documentation Included.
[cited by applicant]
Cok et al., “Synthesis of Model Network Hydrogels via Tetrazine-Olefin Inverse Electron Demand Diels-Alder Cycloaddition,” Macromol Symp, 2013, 329:108-112.
[cited by applicant]
Coviello et al., “Polysaccharide hydrogels for modified release formulations,” Journal of Controlled Release, 2007, vol. 119, pp. 5-24.
[cited by applicant]
Deforest et al., “Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments,” Nature materials: Letters, 2009, vol. 8, pp. 659-664.
[cited by applicant]
Desai et al., “Versatile click alginate hydrogels crosslinked via tetrazine-norbornene chemistry,” Biomaterials, 2015, vol. 50, pp. 30-37.
[cited by applicant]
Devaraj et al., “Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/trans-Cyclooctene Cycloaddition,” Angew. Chem. Int. Ed., 2009, vol. 48, pp. 7013-7016.
[cited by applicant]
Devaraj et al., “Reactive polymer enables efficient in vivo bioorthogonal chemistry,” PNAS, 2012, vol. 109, No. 13, pp. 4762-4767.
[cited by applicant]
Eckhouse et al., “Local Hydrogel Release of Recombinant TIMP-3 Attenuates Adverse Left Ventricular Remodeling After Experimental Myocardial Infarction,” Science Translation Medicine, 2014, vol. 6, Issue 223, 10 pages.
[cited by applicant]
Eschenhagen et al., “Physiological aspects of cardiac tissue engineering,” Am. J. Physiol. Heart Circ. Physiol., vol. 30, 2012, pp. H133-H143.
[cited by applicant]
European Application No. 14813532.0, Extended European Search Report mailed Dec. 2, 2016, 9 pages.
[cited by applicant]
Extended European Search Report from the European Patent Office for Application No. 16845300.9 dated Apr. 17, 2019 (13 pages).
[cited by applicant]
Extended European Search Report mailed on Aug. 10, 2017, for EP Application No. 15761367.0, filed Aug. 10, 2017, 12 pages.
[cited by applicant]
Godoy et al., “Enhanced activity of an immobilized lipase promoted by site-directed chemical modification with polymers,” Process Biochemistry, 2010, 45(4):534-541.
[cited by applicant]
Guo Hua et al: “Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy”, International Journal of Pharmaceutics, Els ev i er, N L, vol. 451, No…
[cited by applicant]
Hashida et al., “Timed-Release of Mitomycin C from Its Agarose Bead Conjugate,” Chem Pharm Bull, 1977, 25:2456-2458.
[cited by applicant]
Hofmann et al., “Targeted delivery of vancomycin to
[cited by applicant]
Hu et al., “Mitochondria-Targeted Cancer Therapy Using a Light-Up Probe with Aggregation-Induced-Emission Characteristics,” Angew. Chem. Int. Ed., 2014, 53:14225-14229.
[cited by applicant]
International Application No. PCT/US2015/020718 , “International Search Report and Written Opinion”, mailed Jun. 10, 2015, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2016/051394 dated Feb. 16, 2017 (21 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/043020 dated Oct. 6, 2014 (9 pages).
[cited by applicant]
IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30.
[cited by applicant]
Jose M. Mejia Oneto et al: In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma11 , ACS Central Science, vol. 2, No. 7, Jul. 13, 2016 (Jul. 13, 2016), pp. 476-482.
[cited by applicant]
Kharkar et al., “Designing degradable hydrogels for orthogonal control of cell microenvironments,” Chem. Soc. Rev., vol. 42, No. 17, pp. 7335-7372 (2013).
[cited by applicant]
Kojima et al., “Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate,” Chem Pharm Bull, 1978, 26(6): 1818-1824.
[cited by applicant]
Koo et al., “Bioorthogonal Copper-Free Click Chemistry In Vivo for Tumor-Targeted Delivery of Nanoparticles,” Angew. Chem. Int. Ed., 2012, vol. 51, pp. 11836-11840.
[cited by applicant]
Korpela et al., “A simple method to introduce aldehydic function to agarose,” Anal Biochem, 1976, 71 (1):322-323.
[cited by applicant]
Koshy et al., “Click-Crosslinked Injectable Gelatin Hydrogels,” Advanced Healthcare Materials, 2016, DOI: 10.1002/adhm.201500757, 7 pages.
[cited by applicant]
Landa et al., “Effect of Injectable Alginate Implant on Cardiac Remodeling and Function After Recent and Old Infarcts in Rat,” Circulation, 2008, vol. 117, pp. 1388-1396.
[cited by applicant]
Li et al., “Designing hydrogels for controlled drug delivery,” Nature Reviews Materials, 2016, 1(12): 38 pages.
[cited by applicant]
Li et al., “Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells,” Natural Chemical Biology, Advanced Online Publication, 2014, vol. 10, 5 pages.
[cited by applicant]
Li et al., “Monodispersed PEG-DOTA Conjugated Anti-Tag-72 Diabody Has Low Kidney Uptake and High Tumor to Blood Ratios Resulting in Inproved
[cited by applicant]
Lueckgen et al., “Hydrolytically-degradable click-crosslinked alginate hydrogels,” Biomaterials, 2018, 181: 189-198.
[cited by applicant]
Matikonda et al., “Bioorthogonal prodrug activation driven by a strain-promoted 1,3-dipolar cycloaddition,” Chem. Sci., 2015, vol. 6, pp. 1212-1218.
[cited by applicant]
Mejia Oneto et al., “Implantable biomaterial based on click chemistry for targeting small molecules,” Acta Biomaterialia, 2014, vol. 10, pp. 5099-5105.
[cited by applicant]
Neves et al., “Imaging Cell Surface Glycosylation in Vivo Using “Double Click” Chemistry,” Bioconjugate Chem., May 5, 2013, vol. 24, pp. 934-941.
[cited by applicant]
Niska et al., “Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental
[cited by applicant]
Patterson et al., “Finding the Right (Bioorthogonal) Chemistry,” ACS Chem. Biol., 2014, vol. 9, pp. 592-605.
[cited by applicant]
Pretze et al., “Recent Trends in Bioorthogonal Click-Radiolabeling Reactions Using Fluorine-18,” Molecules, vol. 18, 2013, pp. 8618-8665; doi:I0.3390/molecules18078618.
[cited by applicant]
Reiner et al., “The inverse electron demand Diels-Alder click reaction in radiochemistry,” J. Labelled Comp. Radiopharm., 2014, vol. 57, No. 4, pp. 285-290.
[cited by applicant]
Rohatagi et al., “Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration,” J. Clin. Pharmacol., 1995, 35:1187-1193.
[cited by applicant]
Rossin et al., “Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice,” Nat Commun, 2018, 9:1484, Supplementary Information Included, 120 pages.
[cited by applicant]
Rossin et al., “In Vivo Chemistry for Pretargeted Tumor Imagining in Live Mice,” Angew. Chem. Int. Ed., vol. 49, pp. 3375-3378 (2010) Supporting Information Sections S1-S6, pp. S2-S21.
[cited by applicant]
Rossin et al., “Triggered Drug Release from an Antibody-Drug Conjugate Using Fast “Click- to-Release” Chemistry in Mice,” Bioconjugate Chemistry, 2016, 27:1697-1706.
[cited by applicant]
Royzen et al., “A Photochemical Synthesis of Functionalized trans-Cyclooctenes Driven by Metal Complexation,” J. Am. Chem. Soc., vol. 130, pp. 3760-3761 (2008).
[cited by applicant]
Seif-Naraghi et al., “Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction,” Science Translation Medicine, 2013, vol. 5, Issue 173, 10 pages.
[cited by applicant]
Selvaraj et al., “Tetrazine-tans-cyclooctene ligation for the rapid construction of integrin α
[cited by applicant]
Selvaraj et al., “trans-Cyclooctene—a stable, voracious dienophile for bioorthogonal labeling”, Current Opinion in Chemical Biology, vol. 17, Issue 5, 2013, pp. 753-760; doi: 10.1016/j.cbpa.2013.07.031.
[cited by applicant]
Shelke et al., “Polysaccharide biomaterials for drug delivery and regenerative engineering,” Polym. Adv. Technol., 2014, vol. 25, pp. 448-460; DOI: 10.1002/pat.3266.
[cited by applicant]
Sluyterman et al., “Chromatofocusing: a preparative protein separation method,” TIBS, 1982, pp. 168-170.
[cited by applicant]
Thalhammer et al., “Reaktivitat Einfacher Offenkettiger und Cyclischer Dienophile Bei Diels-Alder-Reaktionen Mit Inversem Elektronenbedarf,” Tetrahedron Letters, 1990, vol. 31, No. 47, pp. 6851-6854.
[cited by applicant]
Thomas et al., “Polyvalent Dendrimer-Methotrexate as a Folate Receptor-Targeted Cancer Therapeutic” Molecular Pharmaceutics, 2012, vol. 9 pp. 2669-2676.
[cited by applicant]
Tjwa, “Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler,” Ann. Allergy Asthma Immunol., 1995, 75(2): 107-111.
[cited by applicant]
Triton et al., “The anticancer agent adriamycin can be actively cytotoxic without entering cells,” Science, 1982, 217(4556):248-250.
[cited by applicant]
Verbeke et al., “Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation,” Adv Healthc Mater, 2017, 6 (6), 34 pages.
[cited by applicant]
Versteegen et al., “Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation,” Angew. Chem. Int. Ed., 2013, vol. 52, pp. 14112-14116.
[cited by applicant]
Versteegen et al., “Click-to-Release from trans-Cyclooctenes: Mechanistic Insights and Expansion of Scope from Established Carbamate to Remarkable Ether Cleavage,” Angew. Chem. Int. Ed., 2018, 57:10494-10499.
[cited by applicant]
Zeglis et al., “A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry,” J. Nucl. Med., 2013, vol. 54, No. 8, pp. 1389-1396.
[cited by applicant]
Zeglis et al., “Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis,” Chemistry Open Communications, 2014, vol. 3, pp. 48-53, DOI: 10.1002/open.201402000.
[cited by applicant]
Zeglis et al., “Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry,” Bioconjugate Chemistry, 2011, vol. 22, p…
[cited by applicant]
Zhang et al., “An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture,” International Journal of Pharmaceutics, 2008, vol. 353, pp. 74-87.
[cited by applicant]
Japanese Patent Office Action for Application No. 2018-532532 dated Aug. 26, 2020 (14 pages, English translation and pending claims included).
[cited by applicant]
Chinese Patent Office Action for Application No. 201680056941.4 dated Jul. 24, 2020 (15 pages, brief English translation and pending claims included).
[cited by applicant]
Australian Patent Office Examination Report for Application No. 2016321431 dated May 12, 2021 (4 pages).
[cited by applicant]
Chinese Patent Office Action for Application No. 201680056941.4 dated Mar. 2, 2021 (X pages, brief English translation and pending claims included).
[cited by applicant]
Japanese Patent Office Notification of Reasons for Rejection for Application No. 2021-000729 dated Jan. 27, 2022 (9 pages including English translation).
[cited by applicant]
Australian Patent Office Action for application No. 2021282425, dated Feb. 17, 2023 (5 pages).
[cited by applicant]
Australian Patent Office Action for application No. 2021282425, dated Oct. 16, 2023 (7 pages).
[cited by applicant]
Japanese Patent Office Decision of Rejection for application No. 2021-000729, dated Oct. 21, 2022 (5 pages with translation).
[cited by applicant]
Zhang, H., et al. “Interfacial bioorthogonal cross-linking.” ACS macro letters 3.8 (2014): 727-731.
[cited by applicant]